Objective To report 2 patients with anti-myelin oligodendrocyte glycoprotein (MOG)-associated encephalitis who were initially misdiagnosed with small vessel primary CNS vasculitis.
The diagnosis of small vessel primary CNS vasculitis is challenging because conventional and brain MRI angiography are negative, and brain biopsy remains as the only definite diagnostic test. 1 However, brain biopsy is invasive and may be uninformative because of sampling error. Here, we describe 2 patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated encephalitis 2 who were initially misdiagnosed with small vessel CNS vasculitis based on biopsy findings. Physicians should be aware of this potential misdiagnosis because it has important clinical implications.
Case 1
A 5-year-old boy presented with 2 weeks of frontal headache and fever. His physical examination showed decreased alertness and bilateral papilledema (table). Brain CT and MRI (figure 1A) were normal, and the CSF showed pleocytosis. Meningoencephalitis was suspected, and he was started on steroids and acyclovir. During the following days, he developed visual hallucinations. There was gradual clinical improvement until complete recovery, and the patient was discharged on steroid taper 1 month later. In the ensuing 4 months, he was readmitted 3 times for relapsing symptoms while weaning from steroids. Repeat brain MRI showed T2 abnormalities in the basal ganglia, cerebellar peduncles, and supratentorial white matter (figure 1B-D), and CSF pleocytosis was identified in all episodes (table). All relapses substantially improved after treatment with steroids. At the last relapse, a conventional brain angiography was inconclusive. Brain biopsy showed infiltrates of lymphocytes involving the wall of small vessels and perivascular areas accompanied by perivascular demyelination ( figure 2A-D) . The patient was diagnosed with primary CNS vasculitis, and he was started on monthly pulses of cyclophosphamide. After the 5th pulse, he developed acute right optic neuritis that was treated with steroids, resulting in little improvement. Extensive blood testing identified an elevation of lipoprotein A (also present in his asymptomatic father), and oral aspirin was added, together with mycophenolate mofetil (MMF) and prednisone. He remained clinically and radiologically stable (figure 1E), with a right eye visual deficit for 2 years; at this time, immunosuppression was weaned, and shortly after stopping the steroids (while on MMF and aspirin), he developed confusion and decreased level of consciousness. MRI showed extensive white matter abnormalities ( figure 1F ) and high serum titer of MOG antibodies (1:640). Retrospective assessment of stored serum and CSF obtained at onset of the disease were also positive for MOG antibodies (serum titer 1:20,480 and CSF 1:320, table). Review of the paraffin block containing the brain biopsy showed that the inflammatory infiltrates were not confined to the vessel wall and also involved the white and gray matter. With these findings, the patient was diagnosed with anti-MOG encephalitis, and treatment with rituximab, azathioprine, and low-dose prednisone was initiated. No more relapses were observed; at the last follow-up, 3 years later, he remained clinically and radiologically stable on azathioprine and low-dose prednisone (eventually discontinued), and the serum titer of MOG immunoglobulin G (IgG) antibodies had decreased (1:80) below the consensus limit of positivity (≥1:160).
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Case 2
A 39-year-old woman with a history of ulcerative colitis treated with mesalamine and budesonide developed severe, progressive left temporo-parietal headache associated with nausea and photophobia. Shortly after neurologic symptom onset, she developed intermittent fever. Peripheral leukocytosis with neutrophilic predominance and elevated C-reactive protein were identified (table). Brain MRI showed hyperintense gyriform fluid-attenuated inversion recovery signal over the left temporal, parietal, and occipital lobes (figure 1G-H). CSF analysis showed pleocytosis and elevated protein concentration, and the patient was started on empiric antibiotics and acyclovir. Six days later, she developed expressive aphasia, confusion, and agitation, and bilateral VI cranial nerve palsies. Repeat brain MRI showed no changes, and CT angiography demonstrated no clear evidence of vasculitis. A biopsy of the left parietal lobe and dura showed interstitial and perivascular lymphocytic infiltrates with marked involvement of the vessel wall (figure 2E-H). There was no clear evidence of demyelination (data not shown). These findings led to suspect CNS vasculitis, and high-dose IV steroids and oral cyclophosphamide were started. Four months later, cyclophosphamide was discontinued because of elevated transaminases. The dose of prednisone was tapered over the course of 2 years. During the follow-up, the brain MRI normalized at 4 months and the neurologic examination at 9 months; her only complaints were mild aphasia when tired and chronic daily headache. Retrospective analysis of stored CSF obtained by the time of symptom onset showed MOG-IgG antibodies (1:8).
Discussion
We describe 2 patients initially diagnosed with small vessel CNS vasculitis but who in fact had anti-MOG-associated encephalitis. The first patient received standard treatment for CNS vasculitis, including cyclophosphamide and steroidsparing drugs. Although this treatment led to initial stabilization of symptoms, the patient developed new relapses until Glossary MMF = mycophenolate mofetil; MOG = myelin oligodendrocyte glycoprotein. he was transitioned to a B-cell depletion therapy with good clinical and serologic response. In the second patient, the finding of MOG antibodies did not change the treatment strategy because she was already clinically stable; however, an earlier detection of these antibodies could have prevented the brain biopsy.
In retrospect, none of these patients fulfilled the criteria for small vessel CNS vasculitis. Although the presence of inflammatory cells in the vessel walls is sufficient to diagnose medium or large vessel vasculitis, signs of vessel damage such as fibrin deposition and/or necrosis (absent in our patients) must also be present to meet the criteria for small vessel vasculitis. Diapedesis of leukocytes takes place in small vessels, and the presence of inflammatory cells in the walls does not necessarily imply a pathologic process. Moreover, the pathology of CNS vasculitis is usually focal or segmental, and the brain biopsy specimen can be negative or not meet the full diagnostic criteria. 4 As our patients reveal, the presence of lymphoid cells in vessel walls must be interpreted with caution, particularly when the differential diagnosis includes encephalitis with lymphocytic infiltrates. In this context, the presence of lymphocytes in the brain parenchyma away from the vessel walls favors secondary involvement of the vessels rather than a primary vasculitic process. Whether other cases of anti-MOG encephalitis may have been misdiagnosed as CNS vasculitis is unknown. There are reports of patients diagnosed with CNS small vessel vasculitis by brain biopsy who later developed myelitis or optic neuritis 5 (symptoms suggestive of MOG encephalitis), 2,3 making us to postulate that this misdiagnosis may not be unusual.
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